STAR

Choroideremia // Clinical Trials // Inherited Retinal Degeneration // Kimberly Stepien // Past // Sep 30 2020

A Randomized, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1) (STAR)

Sponsor: NightstaRx Ltd, a Biogen Company

CLINICALTRIALS.GOVĀ